Tomoko Yamazaki

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Lenvatinib for Anaplastic Thyroid Cancer

Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki et al. · Frontiers in Oncology · 2017 · 188 citations · Full text

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study

Naoshi Horikawa, Tomoko Yamazaki, Namiki Izumi et al. · General Hospital Psychiatry · 2003 · 142 citations

Clinical Course, Hepatology, Psychiatry +10

A Phase II Study of the Safety and Efficacy of Lenvatinib in Patients with Advanced Thyroid Cancer

Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki et al. · Future Oncology · 2019 · 137 citations · Full text